



Luxembourg, 21.12.2022

Public

Environmental and Social Data Sheet

Overview

Project Name:	<i>CELLECTIS (IEU TI)</i>
Project Number:	<i>20220557</i>
Country:	<i>France</i>
Project Description:	The Promoter is a clinical-stage biopharmaceutical company pioneer in the field of gene editing, deploying core proprietary technologies to develop off-the-shelf immunotherapies for several oncology indications.
EIA required:	no
Invest EU sustainability proofing required	yes
Project included in Carbon Footprint Exercise:	no

Environmental and Social Assessment

Environmental Assessment

The project concerns investments in research and development activities carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The research and development activities of the project do not fall under either Annex I or Annex II of the EIA Directive 2011/92/EU amended by Directive 2014/52/EU.

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

Climate Assessment

The project has been assessed for Paris alignment and is considered to be aligned with the policies set out in the Climate Bank Roadmap and/or associated guidance. The Promoter has established an ESG (Environmental, Social, and Governance) Committee composed of board members, in charge notably of ensuring that the ESG issues are taken into account in the corporate strategy. In this context, an external audit on the company's environmental and climate issues is currently ongoing.



Luxembourg, 21.12.2022

Furthermore, the development of allogeneic “off-the-shelf” therapies may have direct positive effects on climate compared to autologous therapies currently available, facilitating the logistics of manufacturing and reducing the cold chain shipments along the supply chain.

Social assessment

The project does not have any significant negative social impacts.

The project expects to generate positive social benefits by promoting innovation and technological breakthroughs in the development of advanced therapy medicinal products, thus offering new potential treatments for unmet medical needs, and enhancing patients’ quality of life.

By supporting skills development and upgrading, the project is expected to provide significant socio-economic benefits, helping to create and retain highly skilled jobs. In this way, it will strengthen regional socio-economic prosperity and position in global value chains, enhance growth and competitiveness of France in Europe and beyond.

Other Environmental and Social Aspects

The Promoter is committed to animal welfare and the responsible use of animals for scientific purposes. Moreover, the Promoter complies with the European Directive 2010/63/EU on the protection of animals used for scientific purposes, where applicable.

The Promoter complies with the European Directives 2001/18/EC and 2009/41/EC on the deliberate release and/or contained use of Genetically Modified Organisms (GMO), where applicable.

Conclusions and Recommendations

The Promoter has effective E&S policies and operating procedures in place, which are in line with industry standards.

The project concerns investments in research and development for which no significant impact on the environment is expected.

Sustainability proofing conclusion: the project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information and based on the review of the likely significant ECS risks and impacts and the mitigation measures and management systems in place, the project is deemed to have low residual ECS risks and impacts. No further sustainability proofing is required.

Considering the above, taking into consideration the Environmental, Social and Climate impacts of this RDI project, including the capacity of the promoter and the overall net positive social impact, this project is deemed acceptable for the Bank’s financing under environmental and social terms.